

## INDEX

- Absorption
  - chemicals, 34–39
  - decreasing, procedures for, 150–157
  - percutaneous, 72–74
- Accumulation
  - chemicals
    - biologic organism, 41–44
    - environment, 7–8
    - genetic factors, 94–95
    - neurohumors, at nerve endings, 161
    - from repeated doses, 113–114
    - resulting in toxicity, 91, 193–194, 198–202
- Acetaminophen
  - metabolism, 62
  - toxic metabolite, 66
- Acetate, in ethanol metabolism, 65
- Acetic acid, dermal toxicity, 193
- Acetylation
  - biotransformation mechanism, 59
  - isoniazid, 91–95
- Acetylcholinesterase
  - active sites, 187
  - direct and indirect inhibitors, 140–141
  - termination of neurohumor action, 161
- Acetyl-CoA, metabolism, citric acid cycle in, 139–140
- Acetylsalicylic acid, *see* Aspirin
- Acetyl sulfanilamide
  - insolubility in urine, 61
  - sulfanilamide conversion to, 64
- Acidic dissociation constant, *see*  $pK_a$
- Acids and bases
  - strong, nonspecific actions, 48
  - weak
    - degree of ionization, 50–55
    - lipid-soluble, 172
- Activation, *see also* Inactivation
  - interspecific differences, 141
  - lymphocytes, 123–125
  - metabolic, 65
  - and suppression, immune system, 133–135
- Activity, animal, evaluation during behavior tests, 243–245
- Adaptation, distinction from tolerance, 68
- Addiction
  - sociologic factors, 118–119
  - tolerance as constant factor, 46
- Additives, food
  - allowable daily intakes, 19
  - combination tests, 218–219
  - no-effect concentration, 226
  - prolonged tests, 214
- Adsorption
  - drug, as inactivation, 114
  - substances, on activated charcoal, 154–155, 159
- Alcohol, *see also* Ethanol; Ethyl alcohol
  - absorbed through oral mucosa, 77
  - abusive use, 254
  - harmful effects, 13
  - toxicity, sociologic factors, 118–119
- Allergic reaction, after hapten exposure, 125

- Allergy immunotherapy, and tolerance, 134
- Allopurinol, drug interactions, 67
- American Conference of Governmental Industrial Hygienists, 75
- Ames Salmonella Assay, 235–236
- Amino acids, reactive groups on, 127–128
- p*-Aminobenzoic acid, competitive inhibition mechanism, 143
- Aminolevulinic acid synthetase, in porphyrin biosynthesis, 99
- Amphetamines
  - optical isomerism, 187
  - toxicity, sociologic factors, 118–119
- Analgesics
  - acetaminophen, 62, 66
  - aspirin, 52–54, 102
- Anemia, hemolytic,
  - primaquine-induced, 94, 96–97
- Anesthetics
  - chloroform, 102
  - interspecific action, 185
  - intrathecal injection, 83
  - phenobarbital, 67–68
  - potency, related to lipid solubility, 54–55
  - summation, 116
  - thiopental, 41–42
- Animals, *see also* Species; *specific animals*
  - behavior tests, 243–245
  - carcinogens, 110
  - different experimental groups, 173–176
  - experimental studies, guidelines, 207–208
  - laboratory, parenteral routes, 79–83
  - qualified data, 15
  - response to carcinogenic agent, 233–234
  - toxicity testing, 204
    - alternatives, 213
  - toxicologic test types, 192
- Antagonistic systems, physiological, 163–164
- Antibacterials, activity, 31–32, 60–61
- Antibiotics
  - hazard versus risk, 254
  - interspecific selectivity, 144
- Antibodies
  - as antidotal agents, 161–162
  - dose-dependent formation, 128
  - production by B cells, 124–125
- Antidotal therapy
  - chelating agents in, 154, 160–161
  - competitive type, 164
  - in economic species, 147–166
  - mechanisms and examples, 152–153
- Antigen–antibody reaction, 122, 129–130, 132
- Antigens
  - recognition by lymphocytes, 123–124
  - subimmunogenic doses, 134
- Apnea, succinylcholine-induced, 91–92, 96
- Arsenic
  - reaction with sulfhydryl groups, 185
  - valence effects, 187–188
- Asphyxiants, acute exposure, 109
- Aspirin
  - induced ulceration, 252
  - intoxication, 102
  - nonionized and ionized forms, 52–54
- Assays
  - Ames Salmonella, 235–236
  - in assessing immune function, 246–248
  - dominant lethal, 229–230
  - host-mediated, 230–231
- Atabrine
  - displacement by primaquine, 44
  - liver concentration in dog, 42
- Atmospheric contaminants, gaseous or vapor, 55
- Atmospheric pollutants
  - concentration variance, 195
  - inhalation route, 74–76

- Atropine**  
antidotal effect on muscarine, 165  
inactivation in rabbits, 45
- Bacteria**  
mutagenesis tests, 229  
resistance to antibacterials, 100  
*Salmonella typhimurium*, mutant strains, 235–236  
selectivity of penicillin, 49  
strains, PABA as nutrient, 143
- BAL**, antidotal agent, 159–160
- Barbiturates**, *see also* Sedatives  
cross-sensitization, 130  
exaggerated pharmacologic actions, 117  
intoxication, 159, 163  
SKF-525A effects, 66  
toxicity, sociologic factors, 118–119
- Barriers**  
to absorption or translocation, 138–139  
blood–brain, 82–83  
imposed by parenteral routes, 80  
membranous  
in dose distribution, 174–175  
in translocation, 35–37  
properties of skin, 72–74
- Bases and acids**  
strong, nonspecific action, 48  
weak  
degree of ionization, 50–55  
lipid-soluble, 172
- B cells**, antibody production, 124–125
- Behavior tests**, 243–245
- Benzoic acid**, cross-sensitization, 130
- Bimolecular equilibrium reaction**, 182
- Binding**, nonspecific, temporary nature, 35–36
- Binding sites**, nonspecific  
relationship to toxicity, 42  
in removal of chemical, 40
- Biologic mechanism**  
challenged, 19–20  
chemical compounds  
essential to, 30–32  
harmful effects, 2–3
- Biologic variation**  
between cells and whole animals, 137–138  
response curves, 20–22
- Biotransformation**, *see also* Transformation  
and chemical solubility changes, 172  
DDT in liver, 79  
dicumarol, 95  
enzymatically induced, 47–48, 55–69  
enzyme systems in, alteration, 194  
inhibition and induction, 65–69  
mechanisms  
selective toxicity due to, 140–142  
synthetic and nonsynthetic, 60–65  
terminating drug action, malfunction, 113–115  
relationship to tolerance, 45  
resulting in more toxic product, 157
- Blindness**, methanol-induced, 157
- Blood**  
aspirin transferred to, 53–54  
chemical translocated to, 148  
chemistry, in toxicity tests, 215  
concentration of compound, 36–37  
sampling at intervals, 214
- Blood–brain barrier**, bypassed, 82–83
- Botulinus toxin**, specific toxicologic effects, 108–109, 142
- Breakdown products**, penicillin, 128–129
- British anti-lewisite**, *see* BAL
- Caesarean section**, animals in teratogenic tests, 224
- Caffeine**, mutagenic test systems for, 230
- Calcium**, serum levels, and response, 31
- Capillaries**, hydrostatic pressures, 37–38
- Carbon monoxide**  
hemoglobin as receptor, 50  
intoxication, 157–158
- Carcinogenicity tests**, 232–236

- Carcinogens**  
 chemical nature, 233–234  
 classified as mutagens, 110–111
- Carrier molecules, lipid-soluble,**  
 37–39
- Catastrophes, resulting in**  
 chemical-induced illness and  
 death, 9
- Categorization, *see also* Classification**  
 toxicity, 25  
 toxicologic responses, 91–94  
 toxicologic tests, 189–191
- Cathartics, for limiting absorption in**  
 intestine, 155
- Causation, chemical**  
 and death, 249–250  
 and diagnosis, 251
- Cell death, selective induction,** 64–65
- Cells**  
 germ and somatic  
   DNA damage, 88  
   mutations, 228  
 interspecific similarities, 183–186  
 natural killer, assay, 247–248  
 responder and stimulator  
   populations, 247  
 undesirable, 144–145
- Charcoal, activated, adsorbed**  
 substances, 154–155, 159
- Chelating agents, in antidotal therapy,**  
 154, 160–161
- Chemical–biological reactions, in**  
 different species, 183–186
- Chemical burns, as nonspecific toxic**  
 action, 48, 108
- Chemicals, *see also* Compounds;**  
**Drugs; Xenobiotics**  
 abnormal response, 121–135  
 absorption and translocation, 34–39  
 accumulated amount, self-limiting,  
 196  
 accumulation and storage, 41–44  
 approximate LD<sub>50</sub>s, 24  
 conjugated by liver, 79  
 expected or normal effects, 103–104  
 harmful effects, 2–3  
   classification, 101–106  
 hazard and benefit, 255–256  
 induced death in U.S., 9, 11–14  
 induced illness and death, 249–251  
 intended for biologic use, 112–119,  
 219  
 as mutagens, 87–88  
 nonspecific and selective actions,  
 48–50  
 normally present in animal, 175–176  
 normal toxic effects, 107–119  
 parenteral routes, 79–83  
 reactant, *see* Receptors  
 repeated topical administration,  
 239–240  
 simultaneous, testing protocols,  
 218–219  
 toxicity, genetic-induced, 88–94  
 translocation, 50–55  
 unexpected or abnormal effects,  
 104–106  
 waste, environmental cycles, 6–8
- Chicken embryo test, as index of**  
 general toxicity, 224–225
- Chlorinated hydrocarbons**  
 hepatotoxicity, 109  
 in wastewater, 8
- Chlorophenothane, *see* DDT**
- Chlorpromazine, side effects,** 115
- Cholinesterase, *see also***  
**Pseudocholinesterase**  
 bound by organophosphates, 42  
 deficiency, 96  
 hydrolysis of procaine, 56
- Chromium, valence effects,** 188
- Chromosomes**  
 aberrations, 228–231  
 human, 86–87
- Chronicity factor, indicating**  
 cumulative nature of compound,  
 201–202
- Circulation, enterohepatic,** 78–79
- Citric acid cycle, in acetyl-CoA**  
 metabolism, 139–140

- Classification, *see also* Categorization  
harmful effects of chemicals,  
101–106
- Competitive inhibition, mechanisms,  
143–144
- Compounds, *see also* Chemicals;  
Drugs; Xenobiotics  
biologically inert, 171  
essential to biologic system, 30–32  
high-dose, administered daily, 218  
inactivation of receptor, 184–185  
initiating sensitization, 126  
life and half-life, in relation to  
toxicity tests, 194–202  
lipid-soluble, absorbed by skin, 74  
new, sensitizing properties, 241–242  
phototoxic reactions, 131–132  
reference, 223–224
- Concentration, *see also* Dose  
chemical  
and response, 30–32  
in routes of exposure, 18–19  
compound in blood, 36–37  
directly related to dose, 173–176  
dose, several and single, 207–208  
excessive, associated toxicity,  
117–119  
final, dependence on membrane  
function, 40–41  
no-effect  
and no-effect dose, controversy,  
177–181  
safety protocol, 226  
normal, associated toxicity, 112–117  
parent chemical, alteration, 140–142  
threshold, 200–201  
tissue, and rate of administration,  
195–197
- Concentration gradient, direction,  
52–54
- Concentration–response factors, in  
toxicologic tests, 172–176
- Confidence  
in chronic toxicity tests, 219–220  
placed on test result, 177–181
- Conjugation  
biotransformation mechanism, 59–60  
chemicals, by liver, 79
- Contact urticaria, inducing agents,  
131–132
- Contaminants  
atmospheric, 55  
food, repeated ingestion, 44  
penicillinic acid as, 128–129
- Control groups  
in carcinogenicity tests, 233–235  
in chronic toxicity tests, 221  
exposed only to solvent, 238  
negative and positive, 178–181,  
223–224, 239
- Cross-sensitization, among benzoic  
acids, 130
- Cumulative response, S-shaped curve,  
21–22
- Curve  
chemical toxic effect, 148–150  
dose–response, 21–23, 25–29  
frequency–response, 89–90  
Gaussian and S-shaped, 20–22
- Cyanide toxicity, antidotal therapy,  
156
- Cyanosis, in presence of  
methemoglobin, 98
- Cytochrome P450  
in biotransformation of  
acetaminophen, 62  
complexed with CO<sub>2</sub>, 57–60  
inactivation, 68
- Cytogenetics, *in vivo*, guidelines,  
231–232
- Damage  
chemical, subsequent tissue  
regeneration, 109  
DNA, germ and somatic cells, 88  
genetic, indicator species for, 230–231  
tissue  
and metabolic activation, 64–65  
repeated, 191–193  
reversibility, 148–149

- Data**  
all-or-none and graded response  
  types, 172–173  
animal, qualified, 15  
extrapolative value, 204  
pathologic and laboratory, 249–250  
toxicologic  
  acquisition, 168  
  requirements, 10  
on weakly active compounds,  
  accuracy, 228
- Database systems, 260–261**
- DDT**  
biotransformation in liver, 79  
LD<sub>50</sub>s, 74  
selective toxicity, 139  
stored in fat, 42
- Death, *see also* Mortality**  
chemical-induced  
  documentation, 249–250  
  and recorded cause, 11–12  
  resulting from catastrophes, 9  
from poisonings, 13–14
- Derivatives**  
dinitrobenzene, 126, 130  
dinitrophenyl, as hapten, 130  
*n*-hydroxy, 2-acetylaminofluorene, 234
- Detoxication**  
by enzymatic biotransformation, 197  
mechanisms  
  impairment, 114  
  normal, 165–166  
  metabolic, 66
- Diagnosis, illness, 250–251**
- Diaphorase, absense, and  
methemoglobin formation, 98**
- Dichlorodiphenyltrichloroethane, *see*  
DDT**
- Dicumarol**  
biotransformation, 95  
combined with plasma, 42  
metabolism, 91  
and vitamin K  
  antagonistic action, 164  
  competition, 144
- Diet**  
versus oral gavage, 77–78  
test, preparation, 217
- Diffusion**  
gases, 54–55  
passive, chemical, 37–39
- Digoxin, intoxication, 162**
- Diisopropyl fluorophosphate, toxicity,  
and route of administration, 81**
- Dilution, chemicals by massive  
environment, 7–8**
- Dimethline, by oral gavage and diet,  
77–78**
- Dimethylnitrosamine, in host-mediated  
assay, 231**
- Dinitrobenzene, nuclear derivatives,  
126, 130**
- Disasters, resulting in chemical-  
induced illness and death, 9**
- Displacement, one chemical agent by  
another, 43–44, 114**
- Distribution, dose, affecting factors,  
174–175**
- Dixyrazine, by oral gavage and diet,  
77–78**
- DNA damage, somatic and germ  
cells, 88**
- Documentation, regarding illness  
causation, 10–11**
- Dog**  
anticancer agent toxicity, 138–139  
drug test results, predictable value  
  for man, 186  
1- and 90-dose LD<sub>50</sub>s, 201  
phenobarbital half-life, 67–68  
protected from sodium cyanide  
  LD<sub>50</sub>, 156  
toxicity tests  
  acute, 209–213  
  chronic, 190, 220–221  
  prolonged, 214–217
- Dominant lethal assay, 229–230**
- Dose, *see also* Concentration; Lethal dose**  
challenging, 128–130  
excessive, 106

- maximally tolerated, 202, 233–236
- microgram, 24–25
- minimally effective, 191, 193
- no-effect
  - and low dose, 15
  - maximum, 219
  - and no-effect level, controversy, 177–181
- and route of administration, 18–19
- subimmunogenic, 134
- terminology, 173–176
- therapeutic, and potency, 27–28
- Dose-range-finding experiment, in acute toxicity tests, 209–210
- Dose–response relationship
  - in chemical biologic effect, 2
  - plotted, 176
  - response curves, 19–22
  - in risk assessment, 252–255
- Draize procedure, in eye tests, 242–243
- Drinking water
  - frequency of intake, 195
  - nationwide monitoring, 8
- Drug interactions
  - indirect, 69
  - resulting in toxicity, 67
- Drugs, *see also* Chemicals; Compounds; Xenobiotics
  - absorption and elimination rates, 197
  - adverse reactions, 131–133
  - analgesic, 52–54, 62, 66, 102, 252
  - antibacterial, 31–32, 60–61
  - antibiotic, 144, 254
  - anticancer, selective toxicity, 138–139
  - barbiturate, 66, 117–119, 130, 159, 163
  - basis of therapeutic use, 26–29
  - combination tests, 218–219
  - combining with receptors, 163–164
  - development, structure–activity relationships, 187–189
  - habit-forming, and tolerance, 45–46
  - hemoglobins sensitive to, 97–99
  - induced death in U.S., 12–14
  - induced toxicity, 101–102
  - narcotic, 118–119, 130
  - by oral gavage and diet, comparison, 77–78
  - protein-bound, 52–53
  - sedative, 151
  - side actions, 26, 113, 115, 254
  - tetracycline, combined with bone, 42
  - therapeutic, hazard versus risk, 254–255
- Economic species
  - antidotal therapy, 147–166
  - and margins of safety, 113
  - as wrong target species, 117
- Economic toxicology, 8–10
- ED<sub>50</sub>, ratio with LD<sub>50</sub>, 27
- Edema, degree, scoring system, 238–239
- EDTA, antidotal agent, 159–160
- Effective dose 50, *see* ED<sub>50</sub>
- Effector site
  - chemical arrival at, 13–14
  - toxic concentration at, 148, 219
- Electrolytes, ionization, 50–52
- Elevation, threshold of toxicity, 162–166
- Elimination, *see also* Excretion
  - chemicals from specific sites, 34
  - enhancement, 157–162
  - rate
    - dependence on nature of chemical, 41–43
    - exceeded by accumulation rate, 193–194
- Embryotoxic effects, experimental, 221–225
- Emetic agents, antagonized by sedative, 151
- Endogenous substances
  - in animals, 175–176
  - variability among species, 31–32

- Enterohepatic circulation, various compounds, 78–79
- Environmental toxicology, 6–8
- Enzymes, *see also specific enzymes*  
competitive inhibition, 143–144  
defective, formation, 90–91  
microsomal drug-metabolizing, 56–69
- Ephedrine, tachyphylactic effects, 45
- Equilibrium, anesthetic agents, 54–55
- Equilibrium reaction, bimolecular, 182
- Erythrocytes, from  
primaquine-sensitive donors, 96–97
- Ethanol, in treatment of methanol intoxication, 157
- Ethyl alcohol, *see also* Alcohol  
induced fat deposition in liver, 199  
metabolism, 41, 65  
teratogenic effects, 111
- Ethylene oxide, induced germinal changes, 88
- Excretion, *see also* Elimination  
chemicals via kidneys, 158–159  
normal mechanisms, 165–166  
prediction from LD<sub>50</sub>s, 82  
routes, 35–36
- Exposure  
asphyxiants, acute, 109  
dusts and primary irritants, 116–117  
haptens, 123–125  
parameters, 251  
repeated  
and enzyme induction, 67–68  
role of exposure intervals, 199–200  
via oral route, 79  
single and repeated, 42–43  
site, xenobiotics captured at, 39
- Extrapolation  
assumptions with regard to, 252–253  
data from  
animals to man, 250–255  
nonmammalian species, 168–169  
species similar to man, 185  
dose–response curves, 181  
practical use, 171  
value of data, 204
- Eye, toxicity tests, 242–243
- Fasting, for prolonged toxicity tests, 217
- Fat  
chemical deposited in, 41–42  
deposition in liver, time-dependence, 199
- Feeding, *ad libitum*, debate, 236
- Fertility, chemical-induced effects, 225
- Fetus, in teratogenic and reproduction tests, 222–228
- Fick's law, gases, 54
- Filtration, chemical, through membrane pores, 37–38
- Fluoroacetate, induced toxicity, 139–140
- Folic acid, preformed, 143
- Food  
additives  
allowable daily intakes, 19  
combination tests, 218–219  
no-effect concentration, 226  
prolonged tests for, 214  
contaminants, repeated ingestion, 44
- Food and Drug Administration, 232, 236
- Forensics, in clinical toxicology, 249–250
- Formaldehyde, captured at site of exposure, 39
- Frequency response, Gaussian curve, 20–21, 89–90
- Function  
cellular, 185–186  
and structure, alterations, 169
- Functional capacity, reserve, organs, 40–41
- Gases  
diffusion, 54–55  
irritant effect, 108  
respiratory, 103



- Gastric lavage, with water or liquid petrolatum, 150–151
- Gastrointestinal tract  
chemical translocation, 77–79  
electrolyte absorption, 52
- Gaussian curve, in frequency response, 20–21, 89
- Gavage, oral, versus diet, 77–78
- Generations, in reproduction tests, 226–228
- Genetics, *see also* Cytogenetics  
in altered responses to chemicals, 94–97  
based chemical toxicity, 88–94  
role in toxicity, 85–106  
in species and strain resistance to toxicity, 99–100
- Gestation, verification, 223
- Glutathione stability test, 97
- Good Laboratory Practice regulations, 248
- Grading, eye irritation, 242–243
- Griseofulvin, dietary and by stomach tube, 78
- Guinea pig, albino, in skin tests, 238–241
- Half-life, *see also* Life  
compounds, in relation to toxicity tests, 194–202  
definition, 34  
phenobarbital, 67–68  
recovery from toxicologic effect, 198–201
- Haptene–allergic mechanism, 132
- Haptens  
complex with proteins, 127, 129  
dinitrophenyl derivative as, 130  
formation in photoallergy reaction, 241  
initial and subsequent exposures, 123–125  
xenobiotic chemicals as, 122
- Harmful effects, *see also* Therapeutic effects  
alcohol, 13  
antidotal therapy for, 147–166  
chemicals  
from accidental exposure, 107–112  
on biologic tissue, 2–3  
classification, 101–106  
intended for biologic use, 112–119  
resulting from withdrawal of xenobiotics, 46  
reversible and irreversible, 28–29
- Hazards  
reversible and irreversible, 255–256  
versus risk, 254–255
- Heavy metals, antidotal therapy, 159–161
- Hematology, in toxicity tests, 215
- Hemoglobin, *see also* Methemoglobin  
abnormal, 94  
drug-sensitive, 97–99  
as receptor for carbon monoxide, 50
- Hemoperfusion, methodology, 159
- Henderson–Hasselbalch equation, 51
- Hepatotoxicity  
acetaminophen, 62, 66  
chlorinated hydrocarbons, 109
- Herbicides, TCDD impurity, 189
- Home cage environment, behavior test, 244
- Host-mediated assay, 230–231
- Human  
acetaldehyde effects, 65  
acetaminophen hepatotoxicity, 62, 66  
antidotal therapy, 147–166  
carcinogens, 110  
chronic toxicity tests, 219–220  
clinical toxicology, 150, 249–256  
exposure to chemicals, 201  
illness or death, chemical-induced, 9, 11–12  
methanol-induced blindness, 157  
methyl mercury toxicity, 44  
qualified animal data applied to, 15

- Human (*continued*)  
 serum calcium concentration and response, 31  
 sulfanilamide effects, 61  
 teratogens, 111  
 thalidomide effects, 111, 115
- Hydrolysis  
 biotransformation mechanism, 59  
 interspecific differences, 141  
 procaine by cholinesterase, 56
- Hydrostatic pressure, capillary, 37–38
- Hydroxylamine, mutagenicity, 228–229
- Hyperactivity, behavior tests for, 244
- Hypersensitivity  
 genetic factors, 96–97  
 involving defective enzyme, 91, 94  
 manifestation, 104  
 not requiring preconditioning, 121  
 as response category, 29–30
- Hyposensitivity, as response category, 29–30
- Illness, *see also* Superinfection  
 chemical-induced  
 documentation and diagnosis, 249–251  
 resulting from catastrophes, 9  
 sublethal, 10–11
- Immune mechanism  
 activation and suppression, 133–135  
 antigen–antibody reaction, 122  
 in toxicology, 125–133
- Immune tests, 245–248
- Immunoglobulins, production, 123–125
- Immunotherapy, allergy, and tolerance, 134
- Inactivation, *see also* Activation  
 adsorption of drug as, 114  
 atropine, in rabbits, 45  
 enzymes, by organophosphates, 161  
 metabolic, concentration-dependent, 174–175  
 receptor, 184–185  
 xenobiotic, and selective toxic action, 140–142
- Indicator species, for genetic damage, 230–231
- Information sources, multidisciplinary, 257–261
- Ingestion, *see also* Oral route  
 offending chemical, antidotal therapy, 150–155  
 repeated, methyl mercury, 44
- Inhalation  
 amyl nitrite, 156  
 atmospheric pollutants, 74–76  
 compound administered by, 207  
 hexane, pathologic sequelae from, 112
- Inheritance, genetic defects, 85–87
- Inhibition, competitive, mechanisms, 143–144
- Injection  
 antigen, in allergy immunotherapy, 134  
 chemicals, various parenteral routes, 79–83  
 sodium nitrite, 156
- Insects  
 DDT toxicity, 139  
 mutants, 100  
 strain resistance to malathion, 140–141
- Intestine  
 poor absorption of chemicals, 54  
 unabsorbed agent, hastening transit, 155–156
- Intoxication  
 aspirin, 102  
 barbiturate, 163  
 carbon monoxide, 157–158  
 cyanide, 156  
 heavy metals, 159–161  
 methanol, 157  
 methyl mercury, 44  
 salt, 151
- In vitro* replacement strategies, for acute toxicity testing, 213
- Ionization, effect on chemical translocation, 50–55

- Ions
  - selective partitioning, 38–39
  - uranyl, bioconcentration, 138
- Ipecac, emetic of choice, 151
- Irradiation
  - effect on immune response, 134
  - in phototoxicity and photoallergy tests, 241–242
- Irreversibility, *see also* Reversibility
  - harmful effects, 28–29
  - hazards, 255–256
  - specific toxicologic effects, 109–111
- Irritation
  - eye, grading, 242–243
  - skin, primary, 238–240
- Isomers, optical
  - amphetamine, 187
  - in selective toxicity, 142–143
- Isoniazid
  - acetylation, 91–95
  - toxicity, and route of administration, 81
- Kidneys
  - bioconcentration of uranyl ions, 138
  - excretion of chemicals, 158–159
  - exposure to chlorinated hydrocarbons, 116–117
  - failure, 252
  - lumen, pH effects, 52–54
- Kinetics
  - chemical–receptor interaction, 182–183
  - in chemical translocation, 34
  - first-order, 196–197
- Laboratories
  - performing tests on commercial scale, 247–248
  - scientific data from, 257
- Lavage, gastric, with water or liquid petrolatum, 150–151
- LD<sub>50</sub>
  - absolute value, 24
  - in acute toxicity testing, 210–213
  - dependence on route of administration, 80–83
  - ratio with ED<sub>50</sub>, 27
  - sodium cyanide, 156
  - and statistical concepts, 22–23
- Lead, excretion rate, 160–161
- Lesions, histological examination, 217–218, 227
- Lethal concentration time, in acute toxicity testing, 210
- Lethal dose, *see also* LD<sub>50</sub>
  - and categories of toxicity, 25–26
- Lethality, order, acute toxicity tests for, 208–213
- Life, *see also* Half-life
  - compound, in relation to toxicity tests, 194–202
- Lipid solubility
  - carrier molecules, 37–39
  - effect on chemical translocation, 50–55
  - role in percutaneous penetration, 74
- Liquid petrolatum, in gastric lavage, 150–151
- Liver
  - acetaminophen toxicity, 62, 66
  - alcohol-induced fat deposition, 199
  - Atabrine concentration, 42
  - chlorinated hydrocarbon toxicity, 109
  - conjugation of chemicals, 79
  - fatty infiltration, 102
  - murine, griseofulvin effects, 78
- Locus of action, chemical, 36
- Lymphocytes
  - activation, 123–125
  - mixed lymphocyte response assay, 246–247
- Malathion, selective toxicity, 140–141
- Malfunction
  - in mechanisms for terminating action of agent, 113–115
  - permanent, as pathologic sequel, 111–112

- Margin of safety
  - infinitely high, 32
  - for practical drug use, 27–28
  - regarding economic species, 113
- Maze, residential, behavior test, 244
- Mechanism of action
  - delineation, 208, 210
  - penicillin, 49
  - selectivity, 32, 185–186
- Medical toxicology, 10–12
- Membranes
  - cellular, pH, 51–54
  - role in translocation, 35–39
- Mercurials, corrosive actions, 117
- Metabolism
  - acetaminophen, 62
  - acetyl-CoA, 139–140
  - dicumarol, 91
  - ethyl alcohol, 65
  - prontosil, 61
- Metabolites, reactive,
  - acetaminophen, 62
- Methanol, treatment with ethanol, 157
- Methemoglobin, *see also* Hemoglobin
  - cyanosis in presence of, 98
  - nitrite-induced, 156
  - sulfanilamide-induced, 61
- Methemoglobinemia, hereditary, 98–99
- Methotrexate, displacement by
  - sulfonamides, 114
- Methyl isocyanate, captured at site of
  - exposure, 39
- Methyl mercury
  - accumulation, 44
  - pathologic sequelae, 112
- Microorganisms, as indicators of
  - genetic damage, 230–231
- Microsomal enzymes, 56–69
- Minigenes, lymphocytes containing,
  - 124–125
- Minimal effective dose
  - caveat, 191
  - summation, 193
- Mixed-function oxidase system, 57–60,
  - 64–65
- Mixed lymphocyte response assay,
  - 246–247
- Monkey, anticancer agent toxicity,
  - 138–139
- Monoamine oxidase
  - inhibitor, pretreatment with, 114
  - oxidation of benzylamine, 56
- Morphine
  - produced respiratory depression,
    - 26–27
  - tolerance, 45–46
- Mortality, *see also* Death
  - percentage, conversion to probits, 23
- Mouse
  - carcinogenic studies, 234–236
  - dominant lethal test, 229–230
  - griseofulvin-induced pathology, 78
  - longevity, chemical effect, 178
  - reproduction studies, 227
  - toxicity tests
    - acute, 209–213
    - chronic, 190
    - white, skin tests, 238–240
- Muscarine, antidotal effect of atropine,
  - 165
- Mutagenic index, 230
- Mutagenicity
  - risk estimation, 252–253
  - tests for, 228–232
- Mutagens
  - chemicals as, 87–88
  - hydroxylamine, 228–229
- Mutants
  - hemoglobin, 99
  - insect, 100
  - Salmonella typhimurium* strains,
    - 235–236
  - within study group, 89–91
- Mutations
  - dominant lethal, 229–230
  - permitting progeny survival, 87
  - point, 125, 228–229, 231
- NADPH, in microsomal system
  - operation, 57

- Narcotics  
  cross-sensitization, 130  
  toxicity, sociologic factors, 118–119
- National Library of Medicine,  
  databases, 260–261
- National Toxicology Program, 236
- Natural killer cell assay, 247–248
- Necropsy  
  control and test animals, 227  
  at moribundity, 215–217, 235
- Neurohumors  
  accumulation at nerve endings, 161  
  specific receptors, 142
- Neurotoxicity, delayed, 188, 191, 212
- Nitrite, inhaled or injected, 156
- Nitroglycerin  
  absorbed through oral mucosa, 77  
  skin patch, 72
- No observable effect level, 18–19
- Norbormide, species-selective action,  
  142
- Numbers  
  rats, in addition to high-dose group,  
    217–218  
  test animals  
    experimental, 178–181  
    randomly selected, 233  
    reduction, 236  
  virtual, expression of experimental  
    results, 29–30
- Nutrients, PABA, in bacterial strains,  
  143
- Open field technique, behavior test,  
  244
- Optical isomers  
  different actions, 187  
  in selective toxicity, 142–143
- Oral route, *see also* Ingestion  
  in prolonged tests, 214  
  and translocation cycle, 76–79, 148  
  volume administered by, 206–207
- Orfila, M.J.B., father of modern  
  toxicology, 3–4
- Organogenesis, malformation,  
  chemical-induced, 222–223
- Organophosphates  
  inactivation of enzymes, 161  
  inhibition of cholinesterase, 42  
  LD<sub>50</sub>s, 82  
  percutaneous toxicities, 73  
  selective toxicity, 140–141
- Organs, *see also specific organs*  
  histologic examinations, 216  
  reserve functional capacity, 40–41
- Oxidation, biotransformation  
  mechanism, 58
- Oxygen, treatment of carbon  
  monoxide intoxication, 157–158
- PABA, *see p-Aminobenzoic acid*
- Paracelsus, dose response established  
  by, 4
- Paraoxon, conversion of parathion to,  
  63–64
- Parathion, metabolic conversion, 63–64
- Parenteral routes, *see also* Injection  
  and degree of chemical toxicity,  
    79–83  
  interspecific differences, 206–207
- Partitioning, selective, ions, 38–39
- Pathologic sequelae  
  permanent malfunctions as, 111–112  
  triparanol, 118
- Penicillin  
  formulated with procaine, 82  
  induced defective cell walls, 144  
  mechanism of action, 49  
  sensitization to, 128–129
- Pentobarbital toxicity, and route of  
  administration, 81
- Percutaneous route, absorption rates,  
  72–74
- Pesticides  
  development, structure–activity  
    relationship, 187–189  
  inhibition of enzymes, 68  
  metabolically transformed, 63–64  
  potentiation, 116

- pH  
 and  $pK_a$ , 51–54  
 urine, 158–159
- Phenylbutazone, displacement of warfarin, 114
- Phenylhydrazine, induced hemolytic anemia, 97
- Phenylhydroxylamine, and methemoglobin formation, 98
- Photoallergy tests, 241–242
- Photosensitivity, skin, 131–132
- Phototoxicity tests, 241–242
- Physical–chemical characteristics, compounds, 203
- $pK_a$   
 aspirin and quinine, 158  
 and pH, 51–54
- Pneumonitis, resulting from emetic procedure, 151
- Poisoning, related deaths, 11–14
- Pollutants, atmospheric  
 concentration variance, 195  
 inhalation route, 74–76
- Porphyria, experimentally induced, 99
- Potassium, depletion effects, 175
- Potency  
 anesthetics, related to lipid solubility, 54  
 versus toxicity, 23–26
- Potentiation, among pesticides, 116
- Prediction  
 drug effects in man, 186  
 excretion, from  $LD_{50}$ s, 82  
 optimal dose, 197
- Primaquine  
 displacement of quinacrine, 44  
 induced hemolytic anemia, 94, 96–97
- Probability range limit, arbitrary selection, 23
- Procaine  
 hydrolysis by cholinesterase, 56  
 penicillin formulated with, 82  
 SKF-525A effects, 66  
 toxicity, and route of administration, 81
- Prontosil, antibacterial activity, 60–61
- Proteins  
 abnormal, 91  
 chemicals bound to, 42–44  
 complex with haptens, 127, 129  
 as nonspecific receptors, 52–53  
 plasma, 42, 114
- Protocols  
 modified  $LD_{50}$  tests, 213  
 three-generation study, 226  
 toxicity tests, 189–190, 203
- Prototype, reversion to, in Salmonella, 235
- Pseudocholinesterase, hydrolysis of organic esters, 96
- Purity  
 chemical  
 commercial-grade, 203  
 newly synthesized organic, 189  
 evaluation, 206
- Quinine,  $pK_a$ , 158
- Rabbit  
 albino, in skin tests, 238–240  
 dermal toxicity from acetic acid, 193  
 eye tests, 242–243  
 resistance to atropine, 45
- Radicals  
 halogenated, 126  
 produced by mutagens, 229
- Rat  
 anticancer agent toxicity, 138–139  
 carcinogenic studies, 234–236  
 DDT  $LD_{50}$ s, 74  
 dominant lethal test, 229–230  
 drugs by oral gavage and diet, 78  
 drug test results, predictable value for man, 186  
 norbormide toxicity, 142  
 numbers, in addition to high-dose group, 217–218  
 1- and 90-dose  $LD_{50}$ s, 201  
 reproduction tests, 226–228

- skin permeability, 73
- starvation effects, 66–67
- toxicity tests
  - acute, 209–213
  - chronic, 190, 220–221
  - prolonged, 214–217
- Reactive metabolites,
  - acetaminophen, 62
- Receptors, *see also* Targets
  - chemicals translocated to, 34–35
  - drugs combining with, 163–164
  - interaction with xenobiotics, 137–138
  - presence or absence, and selective toxicity, 142–145
  - specific and nonspecific, 49–50
  - wrong, action on, 115
- Reduction, as biotransformation
  - mechanism, 59
- Regeneration
  - cellular, 198–199
  - tissues, after chemical damage, 109
- Replacement strategies, *in vitro*, for acute toxicity testing, 213
- Reproduction tests, 225–228
- Resistance
  - difference from tolerance, 45
  - species and strains, to toxicity, 99–100
- Respiratory depression
  - antagonized by picrotoxin, 163
  - as morphine side effect, 26–27
- Response
  - abnormal, to chemicals, 121–135
  - categories, 30
  - frequency and cumulative, 20–22
  - graded, 2, 20
    - and all-or-none, 172–173
  - immunologic, 130–133
  - related concepts for essential compounds, 30–32
  - reversible, 191–193
- Reversibility, *see also* Irreversibility
  - chronically induced toxicity, 220–221
  - harmful effects, 28–29
  - hazards, 255–256
  - response, 191–193
  - tissue damage, 148–149
  - toxic effect, 217–218
  - toxicologic effects, 198–199
- Reversion to prototype, in *Salmonella*, 235
- Risk assessment, and data
  - extrapolation, 252–254
- Roudabush method, cutaneous sensitization tests, 240–241
- Route of administration, *see also specific routes*
  - and dose, 18–19
  - effect on systemic toxicity, 71–83
  - of intended use, 170–171
  - selection, for acute toxicity tests, 209–210
  - and time-dependent translocation, 148–149
- Running wheel, behavior test, 244
- Safety, *see also* Margin of safety
  - relationship to benefit, 255–256
  - topical agents, assessment, 237
  - versus toxicity, 26–29
    - experimental concepts, 176–181
    - theoretical concepts, 182–183
  - Salmonella typhimurium*, mutant strains, 235–236
- Salt intoxication, 151
- Schools, United States, teaching of toxicology, 4–5
- Scopolamine, skin patch, 72
- Scoring system, for degrees of redness and of edema, 238–239
- Sedatives, *see also* Barbiturates
  - antagonism of emetic agents, 151
- Selective partitioning, ions, 38–39
- Selectivity
  - cell death induction, 64–65
  - chemical action, 2
    - and mechanism of action, 32, 185–186
  - chemicals, 48–50

- Selectivity (*continued*)  
 interspecific, antibiotics, 144  
 penicillin, for bacteria, 49  
 toxicity, 137–145
- Selenium, induced illness, 175–176
- Sensitization, *see also*  
 Cross-sensitization  
 cutaneous, 237, 240–241  
 penicillin, 128–129  
 relationship to dose, 26–27  
 transferred via serum, 125, 131
- Sensitization reaction  
 adverse drug reactions as, 131–133  
 definition, 121  
 mediators and biologic effects, 126  
 representing chemical-induced  
 toxicity, 135
- Sensitization response, different from  
 pharmacologic response, 132–133
- Serologic tests, sensitivity limits, 128
- Serum  
 calcium concentration, and response, 31  
 sensitization transferred via, 125, 131
- Side actions  
 as action on wrong target organ, 115  
 harmful, and risk, 254  
 at ordinary doses, 113  
 possibly undesirable, 26
- Side effects  
 chlorpromazine, 115  
 drug toxicities as, 102  
 and relative toxicity, 26–27
- SKF-525A, nonspecific microsomal  
 enzyme inhibitor, 65–66
- Skin  
 acetic acid toxicity, 193  
 anatomy, 72–74  
 photosensitivity reactions, 131–132  
 toxicity tests, 237–242  
 xenobiotic nonspecific caustic  
 actions, 107–108
- Skin patch  
 applied in pairs, 241–242  
 chemical concentration, 18  
 nitroglycerin and scopolamine, 72
- Sociologic factors, in toxicity, 118–119
- Soils, chemical contamination, 7–8
- Solubility  
 chemical in biological fluids,  
 171–172  
 limitations, 206–207  
 lipid, *see* Lipid solubility
- Soman, LD<sub>50</sub>s, 82
- Somatic cells, mutations, 88, 228
- Species  
 economic  
 antidotal therapy, 147–166  
 and margins of safety, 113  
 endogenous substance variability,  
 31–32  
 indicator, for genetic damage,  
 230–231  
 nonmammalian, extrapolation of  
 data from, 168–169  
 resistance to toxicity, genetics,  
 99–100  
 submammalian systems, advantages  
 to geneticist, 229  
 suitable for chronic toxicity studies,  
 219–220  
 target, wrong, action on, 117  
 used in acute toxicity tests, 209–213  
 various, chemical–biological  
 reactions, 183–186
- Specificity, toxicologic actions, 108–111
- Starvation, effect on rats, 66–67
- Statistical concepts  
 and LD<sub>50</sub>, 22–23  
 numbers of animals in test group, 181
- Stimulus, for any biological response,  
 182–183
- Stomach  
 emesis, 151  
 lavage with water or liquid  
 petrolatum, 150–151  
 necrotic destruction, 155
- Storage  
 chemicals in biologic organism,  
 41–44  
 test material, 206



- Strains**  
bacteria, PABA as nutrient, 143  
insect, resistance to malathion, 140–141  
mutant and tester, *S. typhimurium*, 235–236  
resistance to toxicity, genetics, 99–100
- Structure, and function, alterations,** 169
- Structure–activity relationship, in toxicologic tests,** 186–189
- Submammalian systems, advantages to geneticist,** 229
- Succinylcholine**  
induced apnea, 91–92  
induced neuromuscular blockade, 95–96
- Sulfanilamide**  
conversion to acetyl sulfanilamide, 64  
metabolic product of prontosil, 60–61
- Sulfhydryl groups, arsenic reaction with,** 185
- Sulfonamides**  
displacement of methotrexate, 114  
lethal action, 143
- Summation**  
action of two drugs, 116  
maximum tissue concentration as result of, 195–196  
minimally effective dose, 193
- Superinfection, *see also* Illness**  
during antibiotic therapy, 115
- Suppression, immune system,** 133–135
- Symposia, and texts, as information sources,** 258
- Synergism, resulting in toxicity,** 116–117
- Tachyphylaxis, difference from tolerance,** 45
- Tannic acid, in universal antidote,** 154–155
- Targets, *see also* Receptors**  
for penicillin, 49  
species, wrong, action on, 115
- TCDD, as impurity in herbicide,** 189
- T cells**  
helper and suppressor, 124–125  
proliferative response, 246–247
- Teratogenicity tests,** 221–225
- Teratogens, in humans,** 111
- Termination of action, enhancement,** 157–162
- Tests**  
analytical and functional, 215  
behavior, 243–245  
carcinogenicity, 232–236  
chicken embryo, 224–225  
cutaneous sensitization, 240–241  
eye, 242–243  
glutathione stability, 97  
immune, 245–248  
mutagenicity, 228–232  
phototoxicity and photoallergy, 241–242  
reproduction, 225–228  
serologic, 128  
skin and eye, 237–243  
special function, 215  
statistical, for significance, 208  
teratogenic, 221–225  
toxicity, *see* Toxicity tests
- 2,3,6,7-Tetrachlorodibenzodioxin, *see* TCDD**
- Tetracycline**  
accumulation, 114  
combined with bone, 42
- Texts, and symposia, as information sources,** 258
- Thalidomide**  
as sedative, 115  
teratogenic effects, 111
- Therapeutic effects, *see also* Harmful effects**  
drugs, 15, 26–29

- Therapeutic effects (*continued*)  
 and second drug effects, 67  
 somatic cell mutations, 88
- Therapy, *see also* Immunotherapy  
 antidotal  
   competitive type, 164  
   in economic species, 147–166  
   hazardous, 251–252  
   mechanisms and examples,  
     152–153
- Thiopental, brief anesthetic action,  
 41–42
- Threshold  
   concentration, 200–201  
   concept, in risk assessment,  
     252–254  
   toxicity, elevation, 162–166
- Threshold limit values  
   modification, 19  
   reviewed annually, 75–76
- Thymus, in immune tests, 245–246
- Time–effect relationship, in toxicity  
 tests, 191–194
- Time interval  
   experimental, 178  
   half-life, 196–197  
   observation of animal, 212–213  
   reproduction tests, 226–228  
   toxicity tests, 190–191
- Time-weighted averages, definition, 75
- Tissues  
   damage  
     and metabolic activation, 64–65  
     repeated, 191–193  
     reversible, 148–149  
   *in vivo* cytogenetic study methods,  
     231–232  
   regeneration after chemical damage,  
     109  
   scar, as pathologic sequel, 112
- TLVs, *see* Threshold Limit Values
- Tolerance  
   acquired over time, 44–46  
   and allergy immunotherapy, 134  
   distinction from adaptation, 68  
   leading to use of greater than  
     normal doses, 118–119
- Toxication, metabolic, 63–64
- Toxicity  
   accumulation, 193, 198–202  
   alkyl mercury in humans, 44  
   definition, 2–3  
   functional and structural,  
     101–102  
   increased, from metabolic  
     conversion, 63–64  
   normally occurring, 179–181  
   versus potency, 23–26  
   reversibility, 217–218, 220–221  
   role of  
     chemical factors, 47–69  
     genetics, 85–106  
   versus safety, 26–29  
     experimental concepts, 176–181  
     theoretical concepts, 182–183  
   selectivity, 137–145  
   systemic, effect of route of  
     administration, 71–83  
   systemic and local, 239  
   threshold, elevation, 162–166
- Toxicity tests  
   acute, 190–191, 208–213  
   categories  
     delineation, 205–206  
     development, 189–191  
   chronic, 219–221  
     for mice, rats, and dogs, 190  
   compound life and half-life in  
     relation to, 194–202  
   concentration–response factors,  
     172–176  
   experimental, 169–170  
   principles, 167–204  
   prolonged, 213–219  
   prolonged and chronic, 194–195, 202  
   protocols, 189–190, 203  
   structure–activity factors, 186–189  
   time–effect relationship, 191–194  
   time interval, 190–191  
   translocation factors, 170–172
- Toxicology  
   clinical, 249–256  
   economic, 8–10

- environmental, 6–8
- fundamental principles, 12–15
- history, 3–4
- immune mechanism in, 125–133
- information sources, 257–261
- medical, 10–12
- modern, scope, 4–6
- Transformation, *see also*
  - Biotransformation
  - cellular, leading to promotional events, 236
  - environmental chemicals, 6–8
  - metabolic
    - chemical, 127–128
    - less toxic compound produced by, 88–89
    - mechanisms, 57–69
  - prontosil, 60–61
- Translocation
  - chemicals via oral route, 77–79
  - decreasing, procedures for, 150–157
  - factors in toxicologic tests, 170–172
  - lipid solubility effects, 50–55
  - membranous barrier effects, 34–39
  - resulting in selective toxicity, 138–140
  - time-dependence, 148
- Transpeptidase system, as target for penicillin, 49
- Treatment, chemical-induced illness, 251–252
- 2,4,5-Trichlorophenoxyacetic acid, toxic impurity, 189
- Triparanol, pathologic sequelae, 118
- Tumorigenicity, normal incidence of occurrence, 181
- Tumors, types, 232–233
- Tyramine, accumulation, 114
- Ulceration, aspirin-induced, 252
- United States
  - chemical-induced deaths, 11–14
  - regulatory agencies, 10, 75–76
  - sociologic factors in drug toxicities, 118–119
  - teaching of toxicology, 4–5
- Universal antidote, 154–155, 165
- Uranium bicarbonate, selective toxicity, 138
- Urine
  - acetylated isoniazid excreted in, 95
  - alkalinization, 53–54
  - analyses, in toxicity tests, 215
  - insolubility of acetyl sulfanilamide, 61
  - pH, 158–159
- Urticaria, contact, inducing agents, 131–132
- Valence, arsenic, effect on toxicity, 187–188
- Variation, biologic
  - intraspecific, 173, 175
  - response curves, 20–22
- Virtual numbers, expression of experimental results, 29–30
- Vitamin A, deficiency in gravid rat, 222–223
- Vitamin K, and dicumarol
  - antagonistic action, 164
  - competition, 144
- Warfarin
  - chronicity factor, 202
  - displacement by phenylbutazone, 114
- Waste chemicals, environmental cycles, 6–8
- Water, *see also* Drinking water
  - in gastric lavage, 150–151
  - as solute of choice, 206–207
  - transfer across membranes, 39
- Xenobiotics, *see also* Chemicals; Compounds; Drugs
  - captured at site of exposure, 39

**Xenobiotics** (*continued*)

enzyme action on, 57–60

as incomplete antigens, 122

interaction with receptor, 137–138

normal effects on biologic tissue,

104

toxicities, 102

withdrawal, harmful effects resulting

from, 46

**Zero-effect, estimation, 176**